Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769744 | 0.76 | EPHX2 (1.00) | KCNA5EPHX2 | |
| SCHEMBL11443225 | 0.75 | KCNA5 (0.57) | KCNA5EPHX2TP53SMN1; SMN2ACHE | |
| SCHEMBL2768006 | 0.74 | EPHX2 (0.72) | KCNA5EPHX2SMN1; SMN2ACHE | |
| SCHEMBL16259070 | 0.73 | KCNA5 (0.56) | KCNA5EPHX2TP53SMN1; SMN2ACHE | |
| SCHEMBL1760399 | 0.73 | KCNA5 (0.52) | KCNA5EPHX2TP53SMN1; SMN2ACHE | |
| SCHEMBL2769324 | 0.73 | EPHX2 (0.70) | KCNA5EPHX2TP53SMN1; SMN2ACHE | |
| SCHEMBL9828963 | 0.72 | KCNA5 (0.55) | KCNA5EPHX2TP53SMN1; SMN2ACHE | |
| SCHEMBL2767837 | 0.71 | EPHX2 (0.67) | KCNA5EPHX2TP53SMN1; SMN2HTR3A | |
| SCHEMBL3516609 | 0.71 | EPHX2 (0.51) | KCNA5EPHX2TP53SMN1; SMN2ACHE | |
| SCHEMBL2768711 | 0.71 | KCNA5 (0.54) | KCNA5EPHX2TP53SMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | KCNA5 1298/4885EPHX2 2212/4885TP53 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.